CITIUS ONCOLOGY, INC.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTOR$0.56+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2025 · 2024 | ||||
|---|---|---|---|---|
| Cash Flows From Operating Activities: | ||||
| Net loss | $(24,761,369) | $(21,148,747) | ||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||
| Stock-based compensation expense | 8,320,419 | 7,498,817 | ||
| Deferred income tax expense | 1,056,960 | 576,000 | ||
| Changes in operating assets and liabilities: | ||||
| Inventory | (12,649,207) | (2,133,871) | ||
| Prepaid expenses | - | (1,100,000) | ||
| Accounts payable | 9,523,062 | 2,422,577 | ||
| Accrued expenses | 4,093,124 | (259,071) | ||
| Due to related party | 8,924,965 | 14,270,648 | ||
| Net Cash (Used in) Provided By Operating Activities | (5,492,046) | 126,353 | ||
| Cash Flows From Investing Activities: | ||||
| License payments | (5,750,000) | (5,000,000) | ||
| Net Cash Used In Investing Activities | (5,750,000) | (5,000,000) | ||
| Cash Flows From Financing Activities: | ||||
| Net proceeds from issuance of common stock | 15,166,842 | - | ||
| Cash contributed by parent | - | 3,827,944 | ||
| Merger, net | - | (2,754,296) | ||
| Proceeds from issuance of note payable to related party | - | 3,800,111 | ||
| Net Cash Provided By Financing Activities | 15,166,842 | 4,873,759 | ||
| Net Change in Cash and Cash Equivalents | 3,924,796 | 112 | ||
| Cash and Cash Equivalents – Beginning of Year | 112 | - | ||
| Cash and Cash Equivalents – End of Year | $3,924,908 | $112 | ||
| Supplemental Disclosures of Cash Flow Information and Non-cash Activities: | ||||
| IPR&D Milestones included in License Payable | $ | - | $28,400,000 | |
| Capital Contribution of due to related party by parent | $ | - | $33,180,961 | |
| Net Prepaid Manufacturing transferred to Inventory | $1,368,720 | $6,134,895 | ||
| Interest Paid | $187,389 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.